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Background: Symptomatic paroxysmal hypertension without significantly elevated catecholamine concentrations
and with no evidence of an underlying adrenal tumor is known as pseudopheochromocytoma.
Methods: We describe the case of a female patient with paroxysmal hypertensive crises accompanied by
headache, vertigo, tachycardia, nausea and altered mental status. Previously, she was treated for a longer period
with alprazolam due to panic disorder. Causes of secondary hypertension were excluded. Neurological triggers
(intracranial tumor, cerebral vascular lesions, hemorrhage, and epilepsy) could not be detected.
Results: Setting of the diagnosis of pseudopheochromocytoma treatment was initiated with alpha- and beta-blockers
resulting in reduced frequency of symptoms. Alprazolam was restarted at a daily dose of 1 mg. The patient’s clinical
condition improved rapidly and the dosage of alpha- and beta-blockers could be decreased.
Conclusions: We conclude that the withdrawal of an anxiolytic therapeutic regimen may generate sympathetic
overdrive resulting in life-threatening paroxysmal malignant hypertension and secondary encephalopathy. We
emphasize that pseudopheochromocytoma can be diagnosed only after exclusion of the secondary causes of
hypertension. We highlight the importance of a psychopharmacological approach to this clinical entity.
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Pseudopheochromocytoma is a rapid onset of a constella-
tion of symptoms generated by sympathoadrenal overdrive
[1,2]. In most cases, this clinical syndrome includes
paroxysmal (malignant) hypertension, tremor, palpitation,
sweating, chest pain, headache, nausea, dizziness, and
pseudoseizures [3-5]. The episodes of clinical symptoms
and complaints may last from minutes up to hours.
Importantly, the basic difference between pheochro-
mocytoma and pseudopheochromocytoma is that in
the latter no biochemical and anatomical background
can be clarified; however, evidence of mild to moderate
catecholamine release may be proven during any of the
paroxysms [6-9]. It has been suggested that a number of
factors interact leading to the development of this clinical
condition in any one individual (Table 1). Furthermore,* Correspondence: szaboz.med@gmail.com
1Division of Emergency Medicine, Institute of Internal Medicine, University of
Debrecen Medical Center, Nagyerdei krt. 98, PO Box 19, 4032 Debrecen,
Hungary
Full list of author information is available at the end of the article
© 2014 Páll et al.; licensee BioMed Central Ltd
Commons Attribution License (http://creativec
reproduction in any medium, provided the or
Dedication waiver (http://creativecommons.or
unless otherwise stated.there are differences in the severity and clinical character-
istics between patients that may result in the diversity of
pseudopheochromocytoma [10]. Interestingly, besides the
already known clinical causes, psychological childhood
traumas may also play a role in the genesis of this clinical
entity, where psychotherapy can effectively relieve symp-
toms [11]. Furthermore, it has to be emphasized that this
condition may be secondary to certain drug therapies (for
example, sympathomimetic agents, tricyclic antidepres-
sants, or reboxetine), all of which can contribute to the
emergence of sympathetic overdrive [12-14]. However, it
has not been clearly elucidated whether the modification
or the termination of a former psychopharmacological
therapy may be able to generate such severe symptoms
leading to the diagnosis of pseudopheochromocytoma
[15]. Throughout our work, we aimed to clarify the role
of the withdrawal of the anxiolytic drug alprazolam in
the genesis of the characteristic clinical features of
pseudopheochromocytoma by presenting one of our
patients’ clinical history.. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Table 1 Various clinical conditions can present in a similar way to pseudopheochromocytoma
Endocrine Hyperthyroidism, carcinoid, mastocytosis, hypoglycemia, insulinoma, menopausal syndrome, adrenal medullary hyperplasia, reninoma
Pharmacologic Tricyclic antidepressants, monoamine oxidase inhibitors, cocaine, alcohol withdrawal, abrupt clonidine withdrawal
Cardiovascular Ischemic heart disease, arrhythmias, baroreflex failure, renovascular disease, postural orthostatic tachycardia syndrome
Neurologic Migraine headache, cluster headache, stroke, diencephalic autonomic epilepsy, meningioma
Other Preeclampsia or eclampsia, obstructive sleep apnea, anxiety or panic attacks, acute intermittent porphyria, recurrent
idiopathic anaphylaxis
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In January 2014, a 55-year-old Caucasian woman was
admitted to our Emergency Unit with paroxysmal malig-
nant hypertension accompanied by headache, vertigo,
tachycardia, lacrimation, nausea and altered mental
status. Her medical history included a caesarean section
(1984), an abdominal surgery due to mechanical ileus, a
laparoscopic cholecystectomy (1995), gastro-oesophageal
reflux and a total thyroidectomy due to a benign non-
toxic multi-nodular goiter, later requiring thyroid hor-
monal substitution. In 2008, an elevated fasting glucose
level pointed to an underlying type 2 diabetes mellitus.
Hypertension and sinus tachycardia was first diagnosed
in 2003. Consequently, the patient underwent several
examinations in various hospitals but no underlying
organic causes of her complaints could be detected.
Endocrinological disorders - especially pheochromocy-
toma - were excluded on several occasions. Her altered
mental status during the hypertensive crises raised the
possibility of neurological deficiency, but no signs of
intracranial tumor, cerebral vascular lesion, hemorrhage
or even epilepsy were detectable. Moreover, cardiac
arrhythmias and ischemic heart disease were also
excluded. Eventually, in 2004, after numerous diagnostic
procedures, panic syndrome was diagnosed; therefore
anxiolytic and antidepressant medications were initiated.
Between 2004 and 2013 the patient was treated with this
combination of psychopharmacological agents. During a
thorough psychiatric follow-up period the frequency of
the paroxysms dropped noticeably, but the patient seemed
to be addicted to the psychopharmacological regimen
so the medications were withdrawn in another center.
During the following year the patient did not show any
clinical symptoms of paroxysmal hypertension. At the
time of the current admission to our clinic the patient’s
medical therapy consisted of metoprolol 100 mg twice
daily, esomeprazole 40 mg daily, levothyroxine 100 μg
daily, allopurinol 100 mg daily, and insulin therapy
(glulisine insulin 3 times a day and glargine insulin
once a day).
The patient presented herself at the Division of Rare
Diseases for further etiologic examinations. During the
first clinical evaluation a very severe attack could be
observed. The patient became unconscious and her blood
pressure rapidly rose to 230/100 mmHg, with a regularheart rate of 160 to 180/minute (Figure 1). Moreover, focal
muscle twitching appeared on her left face, and excessive
lacrimation and flushing could also be observed. Because
of her unstable clinical condition she was immediately
admitted to our ICU. Before the administration of add-
itional medications, the patient’s severe clinical condition
improved significantly without assistance. By the end of
the paroxysm the frequency of sinus rhythm decreased to
90/minute and her blood pressure was also normalized.
After the crisis, no signs of arrhythmia or long-standing
neurological defects could be observed. No other signifi-
cant clinical abnormalities could be found during further
clinical examinations. Afterwards, during the first week of
hospitalization she had attacks two to four times a day.
These paroxysmal hypertensive crises lasted for three to
five minutes and then disappeared spontaneously without
any medical interventions. Between the paroxysms the
patient was asymptomatic. Because of the repeated attacks,
a combination of alpha- and beta-adrenoceptor blockers
was given, which was able to lower her blood pressure and
heart rate during the paroxysms, but not the frequency of
the attacks. Holter electrocardiography recordings and
twelve-lead surface electrocardiograms revealed sudden
onset of episodic sinus tachycardia without any signs of
further atrial or ventricular arrhythmias (Figure 2). Renal
Doppler ultrasound examination was performed to exclude
renovascular disease. It revealed physiological blood flow in
both renal arteries, with no significant difference regarding
resistive indices (0.67 versus 0.7, respectively). Although
previous examinations were not able to prove any endo-
crinological background of the paroxysms, a repeated
laboratory testing of pheochromocytoma and carcinoid
was performed. Laboratory results of our patient are
shown in Table 2. An elevated serum chromogranin A
level appeared, but it proved to be a false positive result
due to concomitant proton-pump inhibitor (PPI) therapy
(after cessation of the PPI, the chromogranin A level
was in the normal range). Surprisingly, an adenoma
could be detected in the left adrenal gland during com-
puted tomography. Due to the repeated severe clinical
symptoms, we were obliged to start treatment of the
pheochromocytoma; thus, a cardio-selective beta-blocker
(bisoprolol 5 mg twice daily) in combination with an
alpha-adrenoceptor-blocker (doxazosine 4 mg once daily)
was initiated. During this time, urine concentrations
Figure 1 During the first clinical evaluation of the patient a very severe attack could be observed. The patient became unconscious, her
systolic blood pressure rapidly rose above 230 mmHg. Similar trends were observed during the repeated paroxysms. BP: blood pressure.
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normetanephrine and dopamine were found to be normal.
Although, we measured slightly elevated serum concentra-
tions of noradrenalin and dopamine during an attack, the
levels did not fulfill the criteria for pheochromocytomaFigure 2 Holter electrocardiogram revealed a paroxysmal sinus tachyca
ventricular arrhythmias (ventricular tachycardia and fibrillation) were observed(Table 3). To ensure the safe exclusion of pheochromo-
cytoma, an iodine-131-metaiodobenzylguanidine (131I-
MIBG) scan was also performed, which did not reveal
any abnormalities relating to adrenal gland dysfunction
(Figure 3). Furthermore, hyperaldosteronism as a veryrdia during the attack. No other atrial arrhythmias or life-threatening
.
Table 2 Laboratory data of the patient
Laboratory variables Results Laboratory references
Na+ 144 133 to146 mmol/L
K+ 4.2 3.5 to 5.3 mmol/L
Cl− 107 99 to 111 mmol/L
Ca2+ (total) 2.33 2.1 to 2.6 mmol/L
Blood urea nitrogen 4.2 3.6 to 7.2 mmol/L
Creatinine 66 44 to 97 μmol/L
eGFR (EPI) 89 > 90 mL/minute/1.73 m2
Glucose 6 3.6 to 6.0 mmol/L
HgbA1C 7.8 4.2 to 6.1 %
Albumin 42 35 to 52 g/L
Total protein 63 60 to 80 g/L
AST 26 < 40 U/L
ALT 38 < 40 U/L
LDH 194 135 to 220 U/L
Alkaline phosphatase 74 40 to 115 U/L
Amylase 23 < 100 U/L
Lipase 17 < 70 U/L
CRP 1.9 < 4.6 mg/L
WBC 8.66 4.8 to 10.8 Giga/L
RBC 3.97 4.2 to 5.4 Tera/L
Hemoglobin 123 115 to 150 g/L
Hematocrit 0.35 0.35 to 0.47
Platelet 277 150 to 400 Giga/L
MCV 88.9 80 to 99 fL
MCH 31 27 to 31 pg
ALT: alanine transaminase; AST: aspartate transaminase; CRP: C reactive
protein; EPI: epidemiology collaboration; GFR: glomerular filtration rate;
HgbA1c: hemoglobin A1c; LDH: lactate dehydrogenase; MCH: mean
corpuscular hemoglobin; MCH: mean corpuscular hemoglobin; MCV: mean
corpuscular volume; MCH: mean corpuscular hemoglobin; MCH: mean
corpuscular hemoglobin; RBC: red blood cell; WBC: white blood cell.
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excluded. Further laboratory tests helped to exclude
any hormonal abnormalities; thus the aforementioned
adrenal gland adenoma was regarded as an ‘incidentaloma’.
Thyroid laboratory tests showed the effective hormonal
substitution of hypothyroidism secondary to the previous
thyroidectomy. After excluding the possibility of endo-
crine disorders we focused on anxiolytic medication.
For this reason psychiatric examination was performed
and alprazolam was re-administered in a daily dose of
1 mg (0.5 mg twice daily). We could demonstrate an
immediate clinical improvement; furthermore, the daily
dose of alpha- and beta-blockers could also be decreased.
During the administration of alprazolam at a daily dose
of 1 mg, sleepiness and fatigue occurred, therefore we
decreased the daily dose to 0.5 mg. Consequently, the
paroxysmal increase in blood pressure reappeared sofurther therapy of 1 mg was necessary for maintenance.
After a four-week period on the ICU, the patient was
discharged though still with mild symptoms but with an
improved quality of life. The systolic and diastolic blood
pressures and heart rate collected after the discharge of
our patient were inserted into the manuscript (Table 4).
Conclusions
The clinical constellation of paroxysmal hypertension
without a clear underlying cause and without proof of
pheochromocytoma has been introduced as pseudo-
pheochromocytoma, which may lead to severe disability
and a worsening quality of life. Importantly, this clinical
entity is characterized by paroxysmal episodes of serious
hypertension and concomitant symptoms due to sympa-
thoadrenal overdrive, which are not related to emotional
stress [16]. However, some patients may experience anxiety
but only in reaction to the distressing symptoms and com-
plaints. On the other hand, panic disorder is characterized
by mild blood pressure elevation where panic and fear are
inevitably discoverable [17]. Despite the different provoking
mechanisms these clinical entities bear resemblance to each
other. Unfortunately, in the case of lacking emotional
distress, paroxysmal hypertension is usually thought to be
an unexplained disorder [1]. Numerous clinical conditions
may manifest as paroxysmal hypertension and should be
clarified where clinically appropriate. Paroxysmal hyper-
tension is mostly accompanied by tachycardia (palpitation)
where the sympathoadrenal system activation is likely
to be the underlying factor. Previously, it has been
shown that patients with pseudopheochromocytoma
show beta- and alpha-1-adrenoceptor hypersensitivity
[6]. The effective response to alpha- and beta-blockers
also seems to support this hypothesis. However, in some
circumstances these drugs are not effective in symptom
control [18]. In these particular cases psychopharmacolog-
ical therapeutic approach may be useful in the prevention
of the paroxysms and restoring quality of life [19]. Previ-
ously, antidepressant agents (desipramine, paroxetine) in
combination with anxiolytic drugs and psychotherapeutic
interventions have been shown to be effective in the
prevention and elimination of the attacks [18]. Import-
antly, the aforementioned management strategy may be
able to control the clinical symptoms but the disease itself
is never eradicated. Moreover, it is important to note that
paroxysmal hypertension and the concomitant symptoms
may be secondary to drug therapy which may raise
sympathetic activity. It has not been established whether
the withdrawal of an anxiolytic therapy may be able to
result in such serious consequences. Benzodiazepines
(for example, alprazolam) are known for their anxiolytic,
sedative, hypnotic, euphoric, anticonvulsant, and muscle
relaxant effects while acting on gamma-aminobutyric
acid A (GABAA) receptors. The GABAA is an ionotropic
Table 3 Hormone levels of the studied patient
Hormonal variables Results Laboratory references
Plasma samples
Thyroid stimulating hormone 2.3 0.3 to 4.2 mU/L
ACTH (8 hours) < 19 < 75 ng/L
Cortisol 245.8 138 to 690 nmol/L
Plasma renin Non- detectable 0.5 to 1.9 x hrs μg/L
Plasma aldosterone 54.1 28 to 291 pmol/l
Chromogranin A (with PPI) 875.4 20 to 100 μg/L
Chromogranin A (without PPI) 48.3 20 to 100 μg/L
Plasma samples during paroxysm
Adrenaline 0.32 < 0.41 nmol/L
Noradrenaline 3.37 0.37 to 2.6 nmol/L
Dopamine 2.73 < 0.88 nmol/L
Urine samples (24-hour collection)
Adrenaline 16 3 to109 nmol/die
Noradrenaline 187 89 to 473 nmol/die
Dopamine 2,171 424 to 1,612 nmol/die
Homovanillic acid 31 9.1 to 33.8 μmol/die
Vanillyl mandelic acid 31 < 34 μmol/die
5-HIAA 23 3.7 to 42.9 μmol/die
Metanephrines 356 375 to 1,506 nmol/die
Normetanephrines 1,340 573 to 1,932 nmol/die
3-metoxytyramine 702 < 900 nmol/die
5-HIAA: 5-hydroxyindoleacetic acid; ACTH: adrenocorticotropic hormone; PPI: proton-pump inhibitor.
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endogenous ligand is GABA, which is an inhibitory
neurotransmitter in the central nervous system. Further-
more, it has been shown that neuronal cholecystokinin
(CCK) receptors are also implicated in these mechanisms
[20]. The CCK receptor activation has been proven toFigure 3 For 131I-MIBG acquisition, 40 MBq radiopharmaceutical was
acquisition were performed on MEDISO AnyScan SC system (Budapest, Hun
projection, 64 views, matrix size 64 × 64. A 16-slice CT was used, with 120
method was performed. None of the adrenal regions showed abnormal fo
Emission Computed Tomography, CT: computed tomography, OSEM: Ordebe responsible for controlling fear and panic attacks.
Consequently, the withdrawal of the benzodiazepines
unarguably can lead to the liberation of CCK receptors
from their inhibition (Figure 4). The concomitant chance
for panic attacks is increased; moreover, alterations in
vascular tone, sudden increase in blood pressure andinjected. A whole body (4 cm/minute) and abdominal SPECT/CT
gary) 72 hours after the injection. SPECT parameters were: 1 minute/
mAs and 120 kV abdominal filter. For the SPECT reconstruction OSEM
cal uptake. MIBG: metaiodobenzylguanidine, SPECT: Single-Photon
red Subset Expectation Maximization.
Table 4 Data on blood pressure and heart rate obtained
after the discharge of our patient revealed the lack of
reoccurrence of the paroxysms
Maximum Minimum Mean
BP sys (mmHg) 145 133 140
BP dia (mmHg) 85 79 82
Heart rate (beats/minute) 93 65 74
BP: blood pressure; dia: diastolic; sys: systolic.
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able sequels [21,22].
In our work we described the medical history of a female
patient who was treated with the anxiolytic drug alprazolam
for years, due to panic disorder. Lately, the anxiolytic
therapy was terminated because her symptoms had
improved and because the danger of addiction was consid-
erable. Recently, our patient was admitted to our center
due to episodes of severe, paroxysmal hypertension with
accompanying symptoms reflecting increased sympathetic
tone. Importantly, these clinical signs were not initiated
by fear or emotional stress. After ruling out all potential
secondary underlying causes that may have contributed
to the worsening of the clinical status, diagnosis of pseu-
dopheochromocytoma was established. Considering the
patient’s severe symptoms, alpha- and beta-adrenoceptor
blocker treatment was introduced, although these drugs
were not effective enough to prevent further paroxysms. ItFigure 4 The effects of benzodiazepines on GABA (gamma-aminobut
hand, binding of GABA molecules to their sites triggers the opening of a c
On the other hand, benzodiazepines are likely to antagonize the CCK-inducwas realized that the cessation of alprazolam treatment
might have been responsible for the sudden worsening
of the clinical condition. Thus, alprazolam therapy was
restarted resulting in a rapid improvement of the patient’s
symptoms and quality of life. The reappearance of ele-
vated blood pressure secondary to the temporary decrease
in the daily dose of alprazolam is considered to be a posi-
tive challenge test.
To our best knowledge, this is the first paper to report
the possible role of anxiolytic withdrawal in the genesis
of pseudopheochromocytoma. Therefore, we emphasize
that the termination of an anxiolytic therapeutic regimen
may generate severe sympathetic overshooting resulting
in life-threatening paroxysmal malignant hypertension and
secondary encephalopathy. We emphasize that pseudo-
pheochromocytoma can be diagnosed only after the exclu-
sion of secondary causes of hypertension. Importantly,
pheochromocytoma has to be safely ruled out. Besides the
administration of alpha- and beta-blockers, we stress the
importance of psychopharmacological and psychothera-
peutic approach to this clinical entity.Informed consent
A written informed consent was obtained from the patient
for the publication of this paper and the accompanying
images.yric acid) receptor and cholecystokinin (CCK) are shown. On one
hloride ion-selective pore resulting in the hyperpolarization of the cell.
ed neuronal activation.
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